Asston Pharma approves preferential allotment of 24 lakh shares at ₹115
- Asston Pharmaceuticals approved preferential allotment of 24,10,431 shares at ₹115 each
- Paid-up equity capital increases to ₹10.92 crore comprising 1,09,22,791 shares
- Top two investors account for over 85% of the total allotment
- Fifteen public category investors participated in the issuance
*this image is generated using AI for illustrative purposes only.
Asston Pharmaceuticals approved the preferential allotment of 24,10,431 equity shares at ₹115 per share on September 5, 2026. The issuance raises the company’s paid-up equity capital to ₹10.92 crore.
The Board of Directors sanctioned the allotment during a meeting that commenced at 10:30 am and concluded at 10:45 am. The shares carry a face value of ₹10 each, with a premium of ₹105 per share payable in cash.
Allotment Details
The company allotted shares to 15 investors, all categorized as public allottees. Vijay Rathee emerged as the largest recipient, acquiring 13,17,391 shares. Vijaylaxmi Infra Projects Private Limited received the second-largest allocation of 7,82,608 shares.
| Allottee Name | Shares Allotted | Category |
|---|---|---|
| Vijay Rathee | 13,17,391 | Public |
| Vijaylaxmi Infra Projects Pvt Ltd | 7,82,608 | Public |
| Shreevardhan Nitin Tupe | 86,956 | Public |
| Swapneel Pradeep Rane | 21,739 | Public |
| Jayaram Chitturi | 21,739 | Public |
| Padamavathi Chitturi | 21,739 | Public |
| Sumit Shrichand Krishnani | 21,739 | Public |
| Yashvardhan Nitin Tupe | 21,739 | Public |
| Neelam Kohli | 21,739 | Public |
| Vijay Boloor | 21,739 | Public |
| Kunal Jeswani | 21,739 | Public |
| Jitender N. Kewalramani | 21,739 | Public |
| Vashi Neha Parimal | 17,391 | Public |
| Harshad Santosh Talreja | 5,217 | Public |
| Riya Kishor Rajani | 5,217 | Public |
| Total | 24,10,431 |
Consequent to this allotment, the total number of equity shares stands at 1,09,22,791. The newly allotted shares rank pari passu in all respects with existing equity shares.
What the Numbers Show
The concentration of allotment is notable, with the top two investors—Vijay Rathee and Vijaylaxmi Infra Projects Private Limited—accounting for approximately 85% of the total shares issued in this round. This suggests significant interest from specific large stakeholders rather than broad-based retail participation.
Historical Stock Returns for Asston Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | -5.71% | -14.58% | +40.66% | +2.99% | -20.77% |
How will the significant capital infusion of ₹2.77 crore impact Asston Pharmaceuticals' liquidity and ability to fund upcoming R&D or expansion projects?
Given that the top two investors hold 85% of the new allotment, what is the strategic relationship between Asston Pharmaceuticals and Vijay Rathee/Vijaylaxmi Infra Projects?
Will this preferential allotment lead to immediate dilution concerns for existing minority shareholders, and how might it affect future dividend policies?
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
